Business Context and Reporting Period
Company: Axcelis Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2009
Business Overview: Axcelis is a worldwide producer of ion implantation and dry strip processing equipment for semiconductor fabrication. The quarter was defined by a severe downturn in the semiconductor capital equipment industry and a major strategic transaction: the sale of the company's 50% interest in its Japanese joint venture, SEN Corporation, to Sumitomo Heavy Industries, Ltd. (SHI).
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $25.7 million | $84.9 million |
| Gross Profit | $3.0 million | $29.2 million |
| Gross Margin | 11.7% | 34.4% |
| Operating Loss | $(25.1) million | $(10.1) million |
| Net Loss | $(29.2) million | $(11.1) million |
| Net Loss Per Share | $(0.28) | $(0.11) |
| Cash and Cash Equivalents (End of Period) | $71.2 million | $68.2 million |
| Net Cash Used in Operating Activities | $(12.1) million | $(12.3) million |
| Net Cash Provided by Investing Activities | $129.2 million | $(1.2) million |
| Net Cash Used in Financing Activities | $(83.2) million | $0.4 million |
Debt and Liquidity: As of March 31, 2009, the company had no outstanding convertible subordinated debt, having repaid the full $85 million obligation using proceeds from the SEN sale. The company currently has no access to credit facilities due to non-compliance with financial covenants on its revolving credit facility.
Material Changes Versus Prior Period
- Revenue Decline: Total revenue decreased 69.7% year-over-year. Product revenue fell from $69.8 million to $17.7 million, and service revenue dropped from $14.0 million to $7.8 million. This was driven by depressed semiconductor market conditions and a loss of market share in high-current ion implant applications.
- Margin Compression: Gross margin collapsed from 34.4% to 11.7%. Product gross margin turned negative (-2.8%) primarily due to a $4.7 million provision for excess inventory and significantly lower system sales volume.
- Operating Expenses: Total operating expenses decreased from $39.3 million to $28.1 million. R&D and Sales & Marketing expenses were reduced significantly due to cost-cutting measures, though General and Administrative expenses increased slightly due to professional fees.
- Restructuring: The company recorded $0.98 million in restructuring charges related to a reduction in force, compared to $0.05 million in the prior year.
- Other Income/Loss: The quarter included a $1.1 million gain on the sale of the SEN investment, offset by a $3.2 million equity loss from SEN prior to the sale.
Guidance, Outlook, and Risks
Management Commentary: Management anticipates significant cash outflows from operations for the remainder of 2009. While the company believes its existing cash ($71.2 million) is sufficient to meet requirements through March 2010, this outlook is contingent on the semiconductor industry not continuing its downturn into 2010. The company is exploring new financing sources but notes that obtaining credit on favorable terms is currently very difficult.
Strategic Shift: Following the sale of SEN, Axcelis no longer receives royalties from SEN. SEN is now free to sell previously licensed products globally, creating a new global competitor. Axcelis intends to expand its own infrastructure in Japan or contract a third party to compete against SEN in that market.
Risks and Contingencies:
- Liquidity Risk: The company has no access to its $50 million revolving credit facility due to covenant violations. Continued operating losses could threaten the company's ability to continue as a going concern if the industry downturn persists.
- Competition: The sale of SEN has created a direct global competitor with access to Axcelis's legacy technology.
- Market Conditions: The semiconductor capital equipment industry is experiencing a prolonged downturn, reducing capital spending by customers.
- Inventory: Approximately $61.7 million of net inventory relates to the Optima product family, which faces market acceptance risks.
Investor Verification Checklist
- Cash Runway: Verify if the $71.2 million cash balance is sufficient to sustain operations through March 2010 given the negative operating cash flow of $12.1 million in Q1.
- Inventory Valuation: Assess the adequacy of the $4.7 million inventory provision and the realizable value of the $61.7 million Optima product inventory.
- Debt Covenant Status: Confirm the status of the $50 million revolving credit facility and the feasibility of regaining compliance with financial covenants.
- Competitive Landscape: Evaluate the impact of SEN Corporation's new ability to sell Axcelis-licensed products globally on Axcelis's future market share and pricing power.
- Optima Product Adoption: Monitor revenue recognition from the Optima HD product line, which generated only $0.2 million in revenue during the quarter.